Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03674-w ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von Tianye He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China. Hauptthemen laut MEDLINE: Telbivudine, Hepatitis B, Chronic, Polymorphism, Single Nucleotide, Antiviral Agents. Die Arbeit nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Sailing Program.
Abstract (Originalsprache)
PURPOSE: To study the correlations of genetic variants of telbivudine phosphorylase kinases and telbivudine plasma concentration with creatine kinase elevation in chronic hepatitis B patients who received telbivudine. METHODS: An observational study was performed in China chronic hepatitis B patients receiving telbivudine therapy at 600 mg once daily. Plasma concentration was measured 12 h after taking telbivudine using ultra-performance liquid chromatography-tandem mass spectrometry and SNPs located in RRM2B, TK2, and NME4 was detected by MALDI-TOF mass spectrometry. All statistical analyses were performed with R 4.3.1 and all graphs were drawn by Origin 2023b and P value < 0.05 was considered statistically significant. RESULTS: A total of 140 patients receiving telbivudine therapy were recruited with a median plasma concentration of 952.49 (781.07-1238.98) ng/mL. The value of plasma concentration was proportional to the grade of creatine kinase elevation and the best telbivudine plasma concentration threshold to discriminate the grade 3/4 CK elevation was 1336.61 ng/mL. Multivariate analysis revealed that plasma concentration and rs3826160 were the independent risk factor of telbivudine-induced creatine kinase elevation. Patients with TC and CC genotype in rs3826160 not only had a higher incidence of creatine kinase elevation but also a higher plasma concentration than TT genotype carriers. CONCLUSION: Chronic hepatitis B patients with TC and CC genotype in rs3826160 have high telbivudine plasma concentration are at risk of elevated creatine kinase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China.
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China. Wangbin@huashan.org.cn.
- Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, 200040, China. 15111030044@fudan.edu.cn.
Förderung
- National Natural Science Foundation of China
- Shanghai Sailing Program
Zitieren
APA
He, T., Chen, B., Li, Y., Song, Y., Wu, J., Xiong, B., Wang, B., & Long, J. (2024). Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03674-w
Vancouver
He T, Chen B, Li Y, Song Y, Wu J, Xiong B, et al. Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03674-w
BibTeX
@article{He2024,
author = {He, Tianye and Chen, Bicui and Li, Yaqun and Song, Yun and Wu, Jian and Xiong, Biyu and Wang, Bin and Long, Jianfei},
title = {Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03674-w}
}
EUVIMED